 Psychedelics biotech company Compass Pathways NASDAQ:CMPS has purchased an intellectual property portfolio that includes patent applications for a variety of psychedelic and empathogenic substances. Compass reached unicorn status after becoming the first company in the sector to IPO on the Nasdaq last year. 